Dataset Information


A long acting nanoformulated lamivudine ProTide.

ABSTRACT: A long acting (LA) hydrophobic and lipophilic lamivudine (3TC) was created as a phosphoramidate pronucleotide (designated M23TC). M23TC improved intracellular delivery of active triphosphate metabolites and enhanced antiretroviral and pharmacokinetic (PK) profiles over the native drug. A single treatment of human monocyte derived macrophages (MDM) with nanoformulated M23TC (NM23TC) improved drug uptake, retention, intracellular 3TC triphosphates and antiretroviral activities in MDM and CD4+ T cells. PK tests of NM23TC administered to Sprague Dawley rats demonstrated sustained prodrug and drug triphosphate levels in blood and tissues for 30 days. The development of NM23TC remains a substantive step forward in producing LA slow effective release antiretrovirals for future clinical translation.

PROVIDER: S-EPMC6945491 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6063073 | BioStudies
| S-EPMC6945494 | BioStudies
| S-EPMC5305294 | BioStudies
| S-EPMC3401515 | BioStudies
| S-EPMC3294959 | BioStudies
| S-EPMC8445934 | BioStudies
| S-EPMC3284210 | BioStudies
| S-EPMC6929995 | BioStudies
2012-01-01 | S-EPMC3374767 | BioStudies
| S-EPMC7033138 | BioStudies